Immuno-oncology studies require some unique considerations. By addressing these issues early in study design, you can help avoid costly delays. Here are four you should prioritize.
Study designs that address precise identification of patients, determine a clinically effective dose, establish specific endpoints and manage safety will help speed your trial to a successful conclusion.
Written by Guest Writer Joy Yucaitis. Yucaitis is Senior Director, Oncology Strategy at Novella Clinical. She provides therapeutic and development consulting to oncology customers, strategic planning for new protocols and executive oversight for key projects. Yucaitis has more than 18 years of oncology drug and diagnostic development experience as both a sponsor and CRO director. For more information, visit novellaclinical.com/oncology.
This article was reprinted from Volume 24, Issue 03, of The CenterWatch Monthly, an industry leading publication providing hard-hitting, authoritative business and financial coverage of the clinical research space. The Action Items section features short columns focusing on actionable or how-to advice from clinical trial professionals. To submit an Action Item, please contact email@example.com. Subscribe >>